X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA CIPLA ALEMBIC PHARMA/
CIPLA
 
P/E (TTM) x 26.6 44.1 60.4% View Chart
P/BV x 6.1 3.6 167.2% View Chart
Dividend Yield % 0.8 0.4 219.5%  

Financials

 ALEMBIC PHARMA   CIPLA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
CIPLA
Mar-17
ALEMBIC PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs792622 127.3%   
Low Rs443458 96.7%   
Sales per share (Unadj.) Rs167.0181.9 91.8%  
Earnings per share (Unadj.) Rs38.212.9 296.5%  
Cash flow per share (Unadj.) Rs42.029.3 143.2%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.4 175.0%  
Book value per share (Unadj.) Rs84.9155.7 54.5%  
Shares outstanding (eoy) m188.52804.51 23.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.73.0 124.5%   
Avg P/E ratio x16.242.0 38.5%  
P/CF ratio (eoy) x14.718.4 79.8%  
Price / Book Value ratio x7.33.5 209.6%  
Dividend payout %10.515.5 67.5%   
Avg Mkt Cap Rs m116,383434,516 26.8%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m4,21426,338 16.0%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m31,487146,302 21.5%  
Other income Rs m552,287 2.4%   
Total revenues Rs m31,542148,589 21.2%   
Gross profit Rs m10,06024,758 40.6%  
Depreciation Rs m72213,229 5.5%   
Interest Rs m371,594 2.3%   
Profit before tax Rs m9,35612,222 76.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2-70 2.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,798 120.2%   
Profit after tax Rs m7,19410,354 69.5%  
Gross profit margin %31.916.9 188.8%  
Effective tax rate %23.114.7 157.0%   
Net profit margin %22.87.1 322.8%  
BALANCE SHEET DATA
Current assets Rs m15,06687,370 17.2%   
Current liabilities Rs m7,67433,081 23.2%   
Net working cap to sales %23.537.1 63.3%  
Current ratio x2.02.6 74.3%  
Inventory Days Days6787 77.0%  
Debtors Days Days4162 65.2%  
Net fixed assets Rs m8,237111,567 7.4%   
Share capital Rs m3771,609 23.4%   
"Free" reserves Rs m15,416123,645 12.5%   
Net worth Rs m16,005125,254 12.8%   
Long term debt Rs m036,454 0.0%   
Total assets Rs m24,594209,532 11.7%  
Interest coverage x255.28.7 2,944.5%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.30.7 183.4%   
Return on assets %29.45.7 515.6%  
Return on equity %44.98.3 543.7%  
Return on capital %58.78.5 690.3%  
Exports to sales %55.734.2 162.9%   
Imports to sales %10.48.3 125.0%   
Exports (fob) Rs m17,55150,050 35.1%   
Imports (cif) Rs m3,28312,203 26.9%   
Fx inflow Rs m17,81151,066 34.9%   
Fx outflow Rs m5,31817,678 30.1%   
Net fx Rs m12,49333,388 37.4%   
CASH FLOW
From Operations Rs m9,30423,824 39.1%  
From Investments Rs m-3,105-13,127 23.7%  
From Financial Activity Rs m-1,959-13,239 14.8%  
Net Cashflow Rs m4,240-2,478 -171.1%  

Share Holding

Indian Promoters % 74.1 16.0 463.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 2.9 12.2 23.8%  
FIIs % 9.1 23.7 38.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 13.9 26.2 53.1%  
Shareholders   49,328 161,166 30.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS